The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to provide a more substantial reduction in body weight and benefit metabolic function, p